113858-90-5

Basic information

• Product Name: ETHYL 5-CYANO-6-MERCAPTO-2-METHYLNICOTINATE
• Synonyms: ETHYL 5-CYANO-6-MERCAPTO-2-METHYLNICOTINATE;ETHYL 3-CYANO-2-MERCAPTO-6-METHYLPYRIDINE-5-CARBOXYLATE
• CAS NO: 113858-90-5
• Molecular Formula: C₁₀H₁₀N₂O₂S
• Molecular Weight: 222.26
• Mol File: 113858-90-5.mol

Chemical Properties

• Boiling Point: 302.8°Cat760mmHg
• Flash Point: 136.9°C
• Appearance: /
• Density: 1.29g/cm³
• Vapor Pressure: 0.000653mmHg at 25°C
• CAS DataBase Reference: ETHYL 5-CYANO-6-MERCAPTO-2-METHYLNICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 5-CYANO-6-MERCAPTO-2-METHYLNICOTINATE(113858-90-5)
• EPA Substance Registry System: ETHYL 5-CYANO-6-MERCAPTO-2-METHYLNICOTINATE(113858-90-5)

Safety Data

• Hazardous Substances Data: 113858-90-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H10N2O2S/c1-3-14-10(13)8-4-7(5-11)9(15)12-6(8)2/h4,13H,3H2,1-2H3/p-1

Upstream product

• 7357-70-2 Cyanothioacetamide 
• 3788-94-1 2-ethoxymethylene-3-oxobutanoic acid ethyl ester 
• 64119-42-2 ethyl 6-chloro-5-cyano-2-methylnicotinate 
• 141-97-9 ethyl acetoacetate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 90113-28-3 ethyl 2-ethoxymethylacetoacetate 
• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 

Downstream Products

• 113859-37-3 N-pyrimidin-6-yl)methyl>amino>benzoyl>-L-glutamic acid 
• 113859-32-8 diethyl N-pyrimidin-6-yl)methyl>amino>benzoyl>-L-glutamate 

Relevant articles and documents

Synthesis of 1-(β-D-glycopyranosyl)-3-deazapyrimidines from 2-hydroxy and 2-mercaptopyridines

The synthesis of new 4- and 5-substituted-3-cyanopyridine nucleosides has been performed by reacting the silylated pyridines and penta-O-aeetyl-α -Dglycopyranose in dichloroethane in the presence of SnCl4. The free nucleosides were tested for their potential activity against HIV and different types of tumor.

Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof

The invention discloses polysubstituted thieno[2,3-b]pyridine derivatives, and a preparation method and an application thereof. The structural formula of the derivatives are represented by formula I shown in the description. A compound for inhibiting a urea transporter is screened by using an erythrocyte model. Experimental results show that the compounds (represented by formula I-1) can inhibit the permeation of a urea transporter UT-B mediated erythrocyte membrane to urea, and the effect of the compounds has a dose-dependent relationship; the compounds represented by the formula I-1 have nocytotoxic effect on MDCK cells within an effective dose range, so the effect of the compounds represented by the formula I-1 on inhibiting cell permeation urea is irrelevant to the cytotoxicity of thecompounds; the inhibition effect of the compounds represented by the formula I-1 on the urea transporter UT-B is gradually enhanced; the inhibiting effect of the compounds represented by the formulaI-1 on the UT-B is reversible; and in-vivo test results show that the compounds represented by the formula I-1 can significantly increase the urination volume of rats, reduce the concentration of ureain rat urine and reduce the osmotic pressure, so that the compounds represented by the formula I-1 generate a urea selective diuresis effect in vivo.

Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors

Cdc7 kinase plays a critical role in the regulation of DNA replication in eukaryotic cells and has been proposed as a target for cancer therapy. We have identified a class of Cdc7/Dbf4 inhibitors with a pyrido-thieno-pyrimidine core structure. Synthesis o

Synthesis of 2,3,5,6-tetrasubstituted pyridines from enamines derived from N,N-dimethylformamide dimethyl acetal

Reactions of 1,3-dicarbonyl compounds with N,N-dimethylformamide dimethyl acetal, followed by cyanothioacetamide or cyanoacetamide and sodium hydride, then acidification, give 5,6-disubstituted 3-cyanopyridine-2(1H)-thiones or 5,6-disubstituted 3-cyanopyridin-2(1H)-ones 4. Analogous reactions with the malononitrile dimer give 5,6-disubstituted 3-cyano-2-(dicyanomethylene)-1,2-dihydropyridines 9.

Chemical synthesis and biological activities of 5-deazaaminopterin analogues bearing substituent(s) at the 5- and/or 7-position(s)

Condensation of cyanothioacetamide (4) with ethyl α-(ethoxymethylene)acetoacetate (5b), ethyl 4-ethoxy-2-(ethoxymethylene)-3-oxobutanoate (5c), ethyl 2-(ethoxymethylene)-3-oxo-4-phenylpropanoate (5d) afforded exclusively the corresponding 6-substituted pyridines (6b-d). Cyclization of 4 with 3-carbethoxybutane-2,4-dione (5e) gave 3-cyano-5-(ethoxycarbonyl)-4,6-dimethylpyridine-2(1H)-thione (6e), whereas reaction of 4 with 3-carbethoxy-1-phenylpropane-1,3-dione (5f) yielded two products, 3-cyano-5-(ethoxycarbonyl)-4-methyl-6-phenylpyridine-2(1H)-thione (6f) and the 6-methyl-4-phenyl isomer 6g. The structural assignments for 6f and 6g are made on the basis of 1H and 13C NMR spectral analyses of the 2-(methylthio)nicotinates (7f,g) prepared from 6f and 6g by treatment with MeI/K2CO3. Nicotinates 7b,d-g were converted into their corresponding 2,4-diaminopyrido[2,3-d]pyrimidines 12b,d-g in five steps, via reduction, protection, oxidation, condensation with guanidine, and deprotection. The 7-mono- and 5,7-disubstituted-5-deazaaminopterins (1b,d-g) were prepared from the respective pyrido[2,3-d]pyrimidines 12b,d-g. Preliminary biological studies showed that 7-methyl and 5,7-dimethyl analogues (1b and 1e) were less active than methotrexate against human leukemic HL-60 and murine L-1210 cells in tissue culture. Compound 1e produced and ILS of 71% at 100 mg/kg per day x 5 (ip) in BDF mice inoculated ip with 106 L-1210 cells.